Rubius Therapeutics hits record low as lead drug's data continues to weigh

Rubius Therapeutics

14/04/2022 20:55

** Rubius Therapeutics  RUBY.O  shares slump nearly 10% to
hit a record low of $1.93 in late afternoon trade
    ** Stock has lost over two-thirds of its value in the last
five sessions following disappointing results from its lead drug
candidate's cancer trial 
    ** Several brokerages, including SVB Leerink and HC
Wainwright, have slashed their target price on the stock
 urn:newsml:reuters.com:*:nL3N2W926M
    ** Including session losses, stock now down nearly 80% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))